Gemtuzumab Ozogamicin Makes a Comeback [News in Brief]

CD33-targeting agent reapproved at a lower dose for AML after studies show benefit outweighs risk.

from Cancer via ola Kala on Inoreader http://ift.tt/2yryphO
via IFTTT